According to the American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update, in patients at high risk for fracture, which of the following pharmacological therapies should be considered for the reduction of hip, nonvertebral, and spine fractures?